Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-4014, an anti-PD-1 antibody for combination therapy; JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2017
Exchange: NASDAQ
Website: jouncetx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/11/2022 | $15.00 → $7.00 | Outperform → Neutral | Robert W. Baird |
| 5/6/2022 | $15.00 → $20.00 | Outperform → Strong Buy | Raymond James |
| 3/16/2022 | $17.00 | Outperform | SMBC Nikko |
| 2/4/2022 | Market Perform → Outperform | Cowen & Co. | |
| 11/5/2021 | $10.00 → $15.00 | Outperform | Raymond James |
| 9/14/2021 | $10.00 | Market Perform → Outperform | Raymond James |
4 - Jounce Therapeutics, Inc. (0001640455) (Issuer)
4 - Jounce Therapeutics, Inc. (0001640455) (Issuer)
3 - Jounce Therapeutics, Inc. (0001640455) (Issuer)
4 - Jounce Therapeutics, Inc. (0001640455) (Issuer)
4 - Jounce Therapeutics, Inc. (0001640455) (Issuer)
4 - Jounce Therapeutics, Inc. (0001640455) (Issuer)
4 - Jounce Therapeutics, Inc. (0001640455) (Issuer)
4 - Jounce Therapeutics, Inc. (0001640455) (Issuer)
4 - Jounce Therapeutics, Inc. (0001640455) (Issuer)
4 - Jounce Therapeutics, Inc. (0001640455) (Issuer)
SC 13G/A - Jounce Therapeutics, Inc. (0001640455) (Subject)
SC 13G - Jounce Therapeutics, Inc. (0001640455) (Subject)
SC 13G/A - Jounce Therapeutics, Inc. (0001640455) (Subject)
SC 13D/A - Jounce Therapeutics, Inc. (0001640455) (Subject)
SC 13G - Jounce Therapeutics, Inc. (0001640455) (Subject)
SC 13D/A - Jounce Therapeutics, Inc. (0001640455) (Subject)
SC 13D/A - Jounce Therapeutics, Inc. (0001640455) (Subject)
SC 13D/A - Jounce Therapeutics, Inc. (0001640455) (Subject)
SC 13D - Jounce Therapeutics, Inc. (0001640455) (Subject)
SC 13G/A - Jounce Therapeutics, Inc. (0001640455) (Subject)
CAMBRIDGE, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of former chief executive officer of Constellation Pharmaceuticals and former Jounce chief business officer, Jigar Raythatha, to its board of directors. "It's incredibly exciting to welcome Jigar to our board of directors. Not only does Jigar bring over 20 years of biotechnology industry experience, but he also comes with a unique position as an early employee of the company at its inception," said Richard Murray, Ph.D., chief executive offic
CAMBRIDGE, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of Dmitri Wiederschain, Ph.D., as Chief Scientific Officer. "The addition of Dmitri to the Jounce team comes at an exciting juncture in our company development," said Richard Murray, Ph.D., chief executive officer and president of Jounce Therapeutics. "Dmitri brings a broad knowledge of contemporary immuno-oncology approaches, tumor immunology and cancer biology. His expertise with preclinical target discovery and first-in-human research will
CAMBRIDGE, Mass., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of Luisa Salter-Cid, Ph.D., to its board of directors. “We are thrilled to welcome Luisa to our board of directors,” said Perry Karsen, chairman of the board of Jounce Therapeutics. “Luisa brings over 20 years of experience in the healthcare industry, specifically in immunology and immuno-oncology, and we look forward to the unique and valuable perspective that her strategic leadership will bring to Jounce.” Dr. Salter-Cid currently serves a
15-12G - Jounce Therapeutics, Inc. (0001640455) (Filer)
EFFECT - Jounce Therapeutics, Inc. (0001640455) (Filer)
EFFECT - Jounce Therapeutics, Inc. (0001640455) (Filer)
25-NSE - Jounce Therapeutics, Inc. (0001640455) (Subject)
S-8 POS - Jounce Therapeutics, Inc. (0001640455) (Filer)
S-8 POS - Jounce Therapeutics, Inc. (0001640455) (Filer)
S-8 POS - Jounce Therapeutics, Inc. (0001640455) (Filer)
S-8 POS - Jounce Therapeutics, Inc. (0001640455) (Filer)
S-8 POS - Jounce Therapeutics, Inc. (0001640455) (Filer)
S-8 POS - Jounce Therapeutics, Inc. (0001640455) (Filer)
Combined group will have a strong clinical pipeline and proven expertise in the discovery and development of highly selective therapeutics for the treatment of cancer and fibrotic disease RXC007, a next-generation selective ROCK2 inhibitor, to lead clinical pipeline; portfolio to include discovery projects from both Redx and Jounce Combined group to be called Redx Inc. listed on Nasdaq under the ticker REDX and led by Redx CEO Lisa Anson with cash runway into H2 2025 ALDERLEY PARK, United Kingdom and CAMBRIDGE, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Redx Pharma (AIM: REDX) and Jounce Therapeutics, Inc. (NASDAQ:JNCE) today announce an unanimously recommended Business Combination of the
- INNATE trial of JTX-8064 +/- pimivalimab Phase 1 Dose Escalation data at ESMO-IO Annual Congress - - SELECT randomized trial of pimivalimab +/- vopratelimab phase 2 data at ESMO-IO Annual Congress - - Two preclinical posters on JTX-1484 and LILRB family at SITC 2022 - - Ended the quarter with $130.3 million in cash, cash equivalents and investments - - Company to host conference call and webcast today at 8:00 AM ET - CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported financial results for the third quart
CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report third quarter 2022 financial results and provide a corporate update on Thursday, November 10, 2022. Jounce Therapeutics' management team will host a webcast and live conference call at 8:00 a.m. ET. Conference Call and WebcastTo access the conference call, please register here and please be advised to do so at least 10 minutes prior to joining the call. The live webcast can be accessed under "Events & Presentations" in the Investors and Me
- INNATE trial of JTX-8064 +/- pimivalimab on track to present preliminary data on at least 80 Phase 2 patients across multiple cohorts by year end - - Patient enrollment complete in the randomized, Phase 2 SELECT trial of vopratelimab in combination with pimivalimab; Data to be reported by year end - - Submitted two abstracts on preclinical LILRB programs to SITC 2022 - - Ended the quarter with $162.3 million in cash, cash equivalents and investments - - Company to host conference call and webcast today at 8:00 AM ET - CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and developmen
CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report second quarter 2022 financial results and provide a corporate update on Thursday, August 4, 2022. Jounce Therapeutics' management team will host a webcast and live conference call at 8:00 a.m. ET. Conference Call and WebcastTo access the conference call, please register here and please be advised to do so at least 10 minutes prior to joining the call. The live webcast can be accessed under "Events & Presentations" in the Investors and Medi
- Two combination cohorts met initial response criteria for continued expansion in INNATE trial of JTX-8064; on track to present data on at least 60 Phase 2 patients across multiple cohorts in 2H2022 - - Target enrollment achieved in SELECT trial of vopratelimab in combination with pimivalimab; data expected in 2H2022 - - Ended the quarter with $186.4 million in cash, cash equivalents and investments - - Company to host conference call and webcast today at 8:00 AM ET - CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and pr
CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report first quarter 2022 financial results and provide a corporate update on Thursday, May 5, 2022. Jounce Therapeutics' management team will host a live conference call and webcast at 8:00 a.m. ET. Conference Call and WebcastTo access the conference call, please dial (866) 916-3380 (domestic) or (210) 874-7772 (international) and refer to conference ID 9072989. The live webcast can be accessed under "Events & Presentations" in the Investors an
CAMBRIDGE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report fourth quarter and full year 2021 financial results and provide a corporate update before market open on Wednesday, March 2, 2022. Jounce Therapeutics' management team will host a live conference call and webcast at 8:00 a.m. ET. Conference Call and Webcast To access the conference call, please dial (866) 916-3380 (domestic) or (210) 874-7772 (international) and refer to conference ID 8998936. The live webcast can be accessed under "E
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report third quarter 2021 financial results and provide a corporate update before market open on Thursday, November 4, 2021. Jounce Therapeutics' management team will host a live conference call and webcast at 8:00 a.m. E.T. Conference Call and WebcastTo access the conference call, please dial (866) 916-3380 (domestic) or (210) 874-7772 (international) and refer to conference ID 6873343. The live webcast can be accessed under "Events & Presenta
Robert W. Baird downgraded Jounce Therapeutics from Outperform to Neutral and set a new price target of $7.00 from $15.00 previously
Raymond James upgraded Jounce Therapeutics from Outperform to Strong Buy and set a new price target of $20.00 from $15.00 previously
SMBC Nikko initiated coverage of Jounce Therapeutics with a rating of Outperform and set a new price target of $17.00
Cowen & Co. upgraded Jounce Therapeutics from Market Perform to Outperform
Raymond James reiterated coverage of Jounce Therapeutics with a rating of Outperform and set a new price target of $15.00 from $10.00 previously
Raymond James upgraded Jounce Therapeutics from Market Perform to Outperform and set a new price target of $10.00
Piper Sandler initiated coverage of Jounce Therapeutics with a rating of Overweight and set a new price target of $20.00
Robert W. Baird resumed coverage of Jounce Therapeutics with a rating of Buy
HC Wainwright resumed coverage of Jounce Therapeutics with a rating of Buy and set a new price target of $15.00 from $11.00 previously
CAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE) ("Jounce" or the "Company"), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Concentra Biosciences, LLC ("Concentra"), through its wholly owned subsidiary Concentra Merger Sub, Inc. ("Concentra Merger Sub"), has successfully completed the previously announced tender offer to acquire all outstanding shares of the common stock of Jounce for $1.85 per share in cash plus a non-tradeable contingent value right (a "CVR") per share. The $1.85 per share upfront consideration represents a premium of approximately
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. ("Jounce" or the "Company") and Redx Pharma plc ("Redx") have agreed to terminate their proposed business combination following the decision by Jounce's Board of Directors to withdraw the recommendation for the all-share merger transaction with Redx (the "Redx Business Combination"). Jounce's decision was based upon the receipt of an unsolicited proposal from Concentra Biosciences, LLC ("Conc
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE) ("Jounce" or the "Company"), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC ("Concentra") will acquire Jounce for $1.85 in cash per share plus a non-tradeable contingent value right (the "CVR"). The $1.85 per share upfront con
CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that patients from the INNATE Phase 2 trial in the ovarian cancer combination cohort with platinum resistant ovarian cancer are experiencing deep and durable responses based on a pre-planned informal data review. The INNATE trial evaluates JTX-8064 as a monotherapy and in combination with the PD-1 inhibitor pimivalimab in patients with advanced solid tumors. JTX-8064, is a humanized IgG4 monoclonal antibody designed to specifically bind to the macrophage rec
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- The Board of Directors (the "Board") of Jounce Therapeutics, Inc. (NASDAQ:JNCE) ("Jounce" or the "Company"), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today confirmed that Concentra Biosciences, LLC ("Concentra"), of which Tang Capital Partners, LP is the controlling shareholder, has made an unsolicited and non-binding proposal ("the Proposal") to acquire
Combined group will have a strong clinical pipeline and proven expertise in the discovery and development of highly selective therapeutics for the treatment of cancer and fibrotic disease RXC007, a next-generation selective ROCK2 inhibitor, to lead clinical pipeline; portfolio to include discovery projects from both Redx and Jounce Combined group to be called Redx Inc. listed on Nasdaq under the ticker REDX and led by Redx CEO Lisa Anson with cash runway into H2 2025 ALDERLEY PARK, United Kingdom and CAMBRIDGE, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Redx Pharma (AIM: REDX) and Jounce Therapeutics, Inc. (NASDAQ:JNCE) today announce an unanimously recommended Business Combination of the
CAMBRIDGE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced today that it is reducing its workforce by approximately 57 percent. The decision to reduce its workforce was made as Jounce believes advancement of its clinical programs, JTX-8064 and vopratelimab, requires funding and a scope that the Company cannot pursue on its own and will be seeking business development opportunities for both programs. "We believe data in both the SELECT and INNATE clinical trials is intriguing, but to date neither study has demonstrated clin
-- Agreement Covers Buyout of Remaining Financial Obligations for Anti-CCR8 Antibody in Development as a Potential Treatment for Solid Tumors -- Gilead Sciences, Inc. (NASDAQ:GILD) and Jounce Therapeutics, Inc. (NASDAQ:JNCE) amended their existing license agreement for GS-1811 (formerly JTX-1811), enabling Gilead to buy out remaining contingent payments potentially due under the license agreement executed in August 2020. As part of the transaction, certain operational obligations of the parties related to GS-1811, an anti-CCR8 antibody, set forth in the license agreement have also been terminated. Gilead will acquire certain related intellectual property, including all outstanding rights o
FOSTER CITY, Calif. and CAMBRIDGE, Mass., Dec. 27, 2022 (GLOBE NEWSWIRE) -- Gilead Sciences, Inc. (NASDAQ:GILD) and Jounce Therapeutics, Inc. (NASDAQ:JNCE) amended their existing license agreement for GS-1811 (formerly JTX-1811), enabling Gilead to buyout remaining contingent payments potentially due under the license agreement executed in August 2020. As part of the transaction, certain operational obligations of the parties related to GS-1811, an anti-CCR8 antibody, set forth in the license agreement have also been terminated. Gilead will acquire certain related intellectual property, including all outstanding rights of Jounce to GS-1811, pursuant to the transaction agreement. GS-1811,
- INNATE trial Phase 1 dose escalation data showed JTX-8064 was well-tolerated as a single agent and in combination with pimivalimab (pimi) - - Patient with advanced biliary tract cancer who failed multiple lines of prior treatment including a PD-1 inhibitor showed a durable partial response with combination treatment - - SELECT randomized Phase 2 trial data showed encouraging trends in the low dose vopratelimab (vopra) arm in combination with pimi compared to pimi alone - - Shorter duration of target engagement with vopra 0.03 mg/kg may avoid T cell exhaustion from agonist stimulation, leading to clinical benefit - CAMBRIDGE, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Jounce The
Jounce Therapeutics, Inc. ("Jounce" or the "Company") and Redx Pharma plc ("Redx") have agreed to terminate their proposed business combination following the decision by Jounce's Board of Directors to withdraw the recommendation for the all-share merger transaction with Redx (the "Redx Business Combination"). Jounce's decision was based upon the receipt of an unsolicited proposal from Concentra Biosciences, LLC ("Concentra"), which led to Jounce entering into a merger agreement whereby Concentra will acquire Jounce through a cash tender offer for all of Jounce's outstanding shares for $1.85 in cash per share plus a non-tradeable contingent value right (the "CVR"). The $1.85 per share upfr
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite trading lower on Monday. The Dow traded up 0.91% to 32,530.40 while the NASDAQ fell 0.09% to 11,813.90. The S&P 500, also rose, gaining, 0.55% to 3,992.68. Check This Out: Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields Leading and Lagging Sectors Energy shares jumped by 2.3% on Monday. Meanwhile, top gainers in the sector included NGL Energy Partners LP (NYSE:NGL), up 10%, and Vista Energy, S.A.B. de C.V. (NYSE:VIST), up 10%. In trading on Monday, communication services shares fell by 1.2%. Top Headline The Dallas Fed manufacturing business index
Gainers Alimera Sciences (NASDAQ:ALIM) shares moved upwards by 33.2% to $1.8 during Monday's regular session. As of 13:30 EST, this security is trading at a volume of 419.3K shares, making up 3567.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $12.6 million. Pyxis Oncology (NASDAQ:PYXS) shares increased by 24.05% to $2.74. Trading volume for this security as of 13:30 EST is 29.2 million, which is 19761.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $101.3 million. As per the news, the Q4 earnings report came out 3 days ago. Delcath Systems (NASDAQ:DCTH) shares increa
Gainers Crown ElectroKinetics Corp. (NASDAQ:CRKN) shares jumped 59.6% to $0.2513. Crown Electrokinetics said it has entered into an agreement with a leading infrastructure solutions provider. First Citizens BancShares, Inc. (NASDAQ:FCNCA) shares surged 42.5% to $829.82 after First-Citizens Bank & Trust Company entered an agreement to purchase all deposits and loans of Silicon Valley Bank. Alpine Acquisition Corporation (NASDAQ:REVE) surged 32% to $14.17. Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) shares jumped 30% to $1.93 after gaining 8% on Friday. Jounce Therapeutics, Inc. (NASDAQ:JNCE) gained 23% to $1.86. Jounce Therapeutics entered into agreement to be acquired by Concent
U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 100 points on Monday. The Dow traded up 0.42% to 32,372.55 while the NASDAQ rose 0.01% to 11,825.46. The S&P 500, also rose, gaining, 0.24% to 3,980.71. Check This Out: Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields Leading and Lagging Sectors Financials shares jumped by 0.9% on Monday. Meanwhile, top gainers in the sector included Communication Services (NASDAQ:FCNCA), up 46%, and Communication Services (NYSE:FRC), up 13%. In trading on Monday, communication services shares fell by 0.6%. Top Headline The Dallas Fed manufacturing business index
Jounce Therapeutics, Inc. (NASDAQ:JNCE) ("Jounce" or the "Company"), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC ("Concentra") will acquire Jounce for $1.85 in cash per share plus a non-tradeable contingent value right (the "CVR"). The $1.85 per share upfront consideration represents a premium of approximately 75% to Jounce's closing share price immediately prior to the March 14, 2023 public disclosure of Concentra's acquisition proposal. Following a thorough review process conducted with the assistance of its